Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate T Simms

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
The Lancet. Public Health|February 15, 2020
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling studyKate T Simms, Sharon J B Hanley, Megan A Smith, et al.
The Lancet. Public Health|December 19, 2017
Cost-effectiveness estimates: the need for complete reporting - Authors' replyJie-Bin Lew, Kate T Simms, Megan A Smith, et al.
The Lancet. Public Health|February 11, 2019
Cancer elimination thresholds: one size does not fit all - Authors' replyMichaela T Hall, Megan A Smith, Julia M L Brotherton, et al.
International Journal of Cancer|February 26, 2021
Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV controlMichaela T Hall, Megan A Smith, Kate T Simms, et al.
Plos One|February 15, 2018
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from AustraliaMichaela T Hall, Kate T Simms, Jie-Bin Lew, et al.
International Journal of Cancer|August 7, 2021
The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry supportAdam Keane, Chiu Wan Ng, Kate T Simms, et al.
International Journal of Cancer|August 20, 2016
Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countriesKate T Simms, Megan A Smith, Jie-Bin Lew, et al.
Plos One|May 7, 2020
The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling studyMichaela T Hall, Megan A Smith, Kate T Simms, et al.
The Lancet. Public Health|February 15, 2020
Projected time to elimination of cervical cancer in the USA: a comparative modelling studyEmily A Burger, Megan A Smith, James Killen, et al.
The Lancet. Public Health|December 19, 2017
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysisKate T Simms, Jean-François Laprise, Megan A Smith, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
The Lancet. Public Health|February 15, 2020
Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling studyKate T Simms, Sharon J B Hanley, Megan A Smith, et al.
The Lancet. Public Health|December 19, 2017
Cost-effectiveness estimates: the need for complete reporting - Authors' replyJie-Bin Lew, Kate T Simms, Megan A Smith, et al.
The Lancet. Public Health|February 11, 2019
Cancer elimination thresholds: one size does not fit all - Authors' replyMichaela T Hall, Megan A Smith, Julia M L Brotherton, et al.
International Journal of Cancer|February 26, 2021
Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV controlMichaela T Hall, Megan A Smith, Kate T Simms, et al.
Plos One|February 15, 2018
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from AustraliaMichaela T Hall, Kate T Simms, Jie-Bin Lew, et al.
International Journal of Cancer|August 7, 2021
The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry supportAdam Keane, Chiu Wan Ng, Kate T Simms, et al.
International Journal of Cancer|August 20, 2016
Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countriesKate T Simms, Megan A Smith, Jie-Bin Lew, et al.
Plos One|May 7, 2020
The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling studyMichaela T Hall, Megan A Smith, Kate T Simms, et al.
The Lancet. Public Health|February 15, 2020
Projected time to elimination of cervical cancer in the USA: a comparative modelling studyEmily A Burger, Megan A Smith, James Killen, et al.
The Lancet. Public Health|December 19, 2017
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysisKate T Simms, Jean-François Laprise, Megan A Smith, et al.
Pageof 4